Serina Therapeutics, Inc. (SER): debt financing — AgeX Therapeutics draws $1M under amended convertible note with Juvenescence; issues warrants for 801,924 shares

Serina Therapeutics, Inc.

On Feb 15, 2023, drew $1M under Amended Secured Convertible Note with Juvenescence Limited.
Up to $2M additional available until May 9, 2023; each draw limited to $1M and subject to Juvenescence's approval.
Warrants for 801,924 shares at exercise price of $0.6235 per share issued in connection with the draw.
Repayment date unchanged at Feb 14, 2024; note secured by security interests in AgeX assets.

item 2.03 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Serina Therapeutics, Inc. incurred senior notes of $1 million with Juvenescence Limited maturing February 14, 2024.

Instrument: senior notes
Principal: $1 million
Counterparty: Juvenescence Limited
Maturity: February 14, 2024
Event: incurrence

Exact text from the filing

On February 15, 2023, AgeX drew $1 million of its available credit under the Amended and Restated Secured Convertible Promissory Note (“Amended Note”) dated February 9, 2023 with Juvenescence Limited (“Juvenescence”).

View on SEC.gov

89 debt financings filed in the last 30 days. Browse all debt financings →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-005435

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.